Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023
Shots:
- The new 52wk. results from a P-IIb trial evaluating povorcitinib in a ratio (1:1:1:1) in 171 patients aged 18-75yrs.
- The results showed mean percentage total body & facial depigmentation improvement from baseline as measured by T-VASI & F-VASI at 52wk. for povorcitinib 15-75mg, 45mg, 75mg, and PBO-to-75mg were 40.7% & 63.6%, 42.7% & 63.8%, 41.3% & 64.4% and 18.1% & 54.8%, respectively
- The 2EPs results incl. ≥50% reduction from baseline in T-VASI (T-VASI50) vs initial results at 24wk. for povorcitinib 15-75mg, 45mg, 75mg and PBO-to-75mg were 45.2%, 37.0%, 37.9% and 15.2%; ≥50% & >75% in F-VASI (F-VASI50 and F-VASI75) were 71.0% & 48.4%, 77.8% & 55.6%, 69.0% & 58.6% and 63.6% & 45.5%, TEAEs of any grade were seen in 89.2% of 83 patients who received 45 or 75 mg doses
Ref: Business wire | Image: Incyte
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
